Shandong Sinobioway Biomedicine Co Ltd (SHE:002581) — Market Cap & Net Worth
Market Cap & Net Worth: Shandong Sinobioway Biomedicine Co Ltd (002581)
Shandong Sinobioway Biomedicine Co Ltd (SHE:002581) has a market capitalization of $379.40 Million (CN¥2.59 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #13822 globally and #4138 in its home market, demonstrating a 7.97% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shandong Sinobioway Biomedicine Co Ltd's stock price CN¥3.93 by its total outstanding shares 659735586 (659.74 Million). Review debt load of Shandong Sinobioway Biomedicine Co Ltd to assess the company's total debt and financial obligations.
Shandong Sinobioway Biomedicine Co Ltd Market Cap History: 2015 to 2026
Shandong Sinobioway Biomedicine Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $3.35 Billion to $379.40 Million (-17.05% CAGR).
Shandong Sinobioway Biomedicine Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shandong Sinobioway Biomedicine Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.85x
Shandong Sinobioway Biomedicine Co Ltd's market cap is 2.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.35 Billion | $858.29 Million | $250.25 Million | 3.90x | 13.39x |
| 2016 | $2.34 Billion | $1.26 Billion | $417.70 Million | 1.85x | 5.61x |
| 2017 | $1.85 Billion | $1.16 Billion | $388.41 Million | 1.59x | 4.76x |
| 2018 | $623.65 Million | $664.59 Million | -$95.79 Million | 0.94x | N/A |
| 2019 | $698.95 Million | $567.64 Million | $63.38 Million | 1.23x | 11.03x |
| 2020 | $1.77 Billion | $276.83 Million | -$195.93 Million | 6.39x | N/A |
| 2021 | $2.06 Billion | $402.71 Million | $271.00 Million | 5.12x | 7.61x |
| 2022 | $1.52 Billion | $357.08 Million | -$14.68 Million | 4.26x | N/A |
| 2023 | $1.41 Billion | $429.79 Million | -$332.46 Million | 3.28x | N/A |
| 2024 | $1.03 Billion | $360.41 Million | -$137.31 Million | 2.85x | N/A |
Competitor Companies of 002581 by Market Capitalization
Companies near Shandong Sinobioway Biomedicine Co Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Shandong Sinobioway Biomedicine Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Shandong Sinobioway Biomedicine Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Shandong Sinobioway Biomedicine Co Ltd's market cap moved from $3.35 Billion to $ 379.40 Million, with a yearly change of -17.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥379.40 Million | -47.60% |
| 2025 | CN¥724.05 Million | -29.51% |
| 2024 | CN¥1.03 Billion | -27.12% |
| 2023 | CN¥1.41 Billion | -7.30% |
| 2022 | CN¥1.52 Billion | -26.23% |
| 2021 | CN¥2.06 Billion | +16.48% |
| 2020 | CN¥1.77 Billion | +153.18% |
| 2019 | CN¥698.95 Million | +12.07% |
| 2018 | CN¥623.65 Million | -66.30% |
| 2017 | CN¥1.85 Billion | -21.01% |
| 2016 | CN¥2.34 Billion | -30.07% |
| 2015 | CN¥3.35 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Shandong Sinobioway Biomedicine Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $379.40 Million USD |
| MoneyControl | $379.40 Million USD |
| MarketWatch | $379.40 Million USD |
| marketcap.company | $379.40 Million USD |
| Reuters | $379.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shandong Sinobioway Biomedicine Co Ltd
Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. The company is involved in the chemical raw materials, chemical product manufacturing, and biopharmaceutical manufacturing; production and sales of medicines. It also offers operating chemical products, such as trimethyl ester and triethyl ester. The company was founded in 2000 and is based in… Read more